An Error Occurred: Forbidden

Oops! An Error Occurred

The server returned a "403 Forbidden".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.
Børs og finans

Gladmelding fra Targovax

Patentsøknad innvilget.

Targovax-sjef Øystein Soug. Foto: Finansavisen

Targovax-sjef Øystein Soug. Foto: Finansavisen

Artikkel av: Odd Steinar Parr
17. januar 2019 - 07.49
An Error Occurred: Forbidden

Oops! An Error Occurred

The server returned a "403 Forbidden".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.

Targovax skriver i en børsmelding torsdag at europeiske patentmyndigheter har godkjent selskapets søknad for RAS-vaksine.

RAS er en genmutasjon som ses i rundt 30 prosent av alle krefttilfeller.

Patentet beskytter RAS-spesifikke T-celler og vaksinene TG01 og TG01 for behandling av kreft i kombinasjon med kjemoterapi.

- Onkologi-markedet vokser stadig, og den største veksten forventes å være i immun-onkologi de kommende årene, sier medgründer og spesialrådgiver Jon Amund Eriksen i en kommentar.

Les mer her.

An Error Occurred: Forbidden

Oops! An Error Occurred

The server returned a "403 Forbidden".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.
An Error Occurred: Forbidden

Oops! An Error Occurred

The server returned a "403 Forbidden".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.